Immune mechanisms in cerebral ischemic tolerance by Lidia Garcia-Bonilla et al.
REVIEW ARTICLE
published: 04 March 2014
doi: 10.3389/fnins.2014.00044
Immune mechanisms in cerebral ischemic tolerance
Lidia Garcia-Bonilla , Corinne Benakis , Jamie Moore , Costantino Iadecola and Josef Anrather*
Brain and Mind Research Institute, Weill Cornell Medical College, New York, NY, USA
Edited by:
Adam Denes, University of
Manchester, UK
Reviewed by:
Sophie Layé, Université Bordeaux,
France
Craig J. Smith, Salford Royal NHS
Foundation Trust, UK
*Correspondence:
Josef Anrather, Brain and Mind
Research Institute, Weill Cornell
Medical College, 407 East 61st
Street, RR-409, New York, NY
10065, USA
e-mail: joa2006@med.cornell.edu
Stressor-induced tolerance is a central mechanism in the response of bacteria, plants, and
animals to potentially harmful environmental challenges. This response is characterized
by immediate changes in cellular metabolism and by the delayed transcriptional activation
or inhibition of genetic programs that are not generally stressor specific (cross-tolerance).
These programs are aimed at countering the deleterious effects of the stressor. While
induction of this response (preconditioning) can be established at the cellular level,
activation of systemic networks is essential for the protection to occur throughout the
organs of the body. This is best signified by the phenomenon of remote ischemic
preconditioning, whereby application of ischemic stress to one tissue or organ induces
ischemic tolerance (IT) in remote organs through humoral, cellular and neural signaling.
The immune system is an essential component in cerebral IT acting simultaneously
both as mediator and target. This dichotomy is based on the fact that activation of
inflammatory pathways is necessary to establish IT and that IT can be, in part, attributed
to a subdued immune activation after index ischemia. Here we describe the components
of the immune system required for induction of IT and review the mechanisms by
which a reprogrammed immune response contributes to the neuroprotection observed
after preconditioning. Learning how local and systemic immune factors participate in
endogenous neuroprotection could lead to the development of new stroke therapies.
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INTRODUCTION
Inflammation is a central component in the pathophysiology of
cerebral ischemia. Brain ischemia triggers both a local and sys-
temic inflammatory response. These responses play contradictory
roles: contributing to progression of the ischemic lesion on one
hand, and to processes of tissue repair in the injured brain on
the other (Iadecola and Anrather, 2011a; Macrez et al., 2011).
Since post-ischemic inflammation shows detrimental and bene-
ficial aspects, anti-inflammatory therapies that indiscriminately
target both arms of this immune response have not been success-
ful (Iadecola and Anrather, 2011a; Macrez et al., 2011). Therefore,
a deeper understanding of post-ischemic inflammation is needed
in order to harness its beneficial effects for therapeutic purposes.
In addition to its beneficial role in the repair and regenera-
tion of ischemic tissue, inflammatory pathways are also involved
in evoking neuroprotective mechanisms that lead to ischemic tol-
erance (IT). The brain is equipped with a remarkable capacity to
mount self-protective programs that are tuned to limit the dele-
terious effects of ischemia, commonly referred to as endogenous
neuroprotection (Iadecola and Anrather, 2011b). These protec-
tive programs can be evoked by preconditioning (PC) stimuli
(Table 1), such as sublethal stressors, resulting in IT (Kirino,
2002; Narayanan et al., 2013). Thus, understanding the endoge-
nous inflammatory pathways involved in brain IT may lead to
novel therapeutic strategies for the prevention and repair of neu-
ronal damage in stroke patients (Shpargel et al., 2008; Macrez
et al., 2011).
Cerebral IT can be acquired by several stimuli including short
episodes of transient focal and global cerebral ischemia, remote
organ ischemia, hypoxia, hypothermia, hyperthermia, exposure
to inhalation anesthetics, cortical spreading depression (CSD),
brief episodes of seizures or by exposure to low-dose bacte-
rial lipopolysaccharide (LPS) prior to cerebral ischemia (Gidday,
2006; Kunz et al., 2007; Shpargel et al., 2008). IT is characterized
by the activation of evolutionary conserved programs that serve
to increase the resistance of the brain to ischemia. In the case of
early preconditioning, these programs can be activated through
preexisting signaling modules that converge in the mitochondria
to improved mitochondrial function and energy metabolism dur-
ing the ischemic event (Dirnagl and Meisel, 2008). In contrast,
delayed PC involves gene transcription and protein synthesis
(Kitagawa et al., 1990). Because activation of transcription is
the main mechanism by which many pro-inflammatory signal-
ing cascades induce a specific cellular response, inflammation is
thought to be a significant component of delayed PC. Table 2
summarizes the inflammatory pathways involved in IT achieved
by different PC stimuli (Table 1). Inflammation is activated by
innate immune receptors such as Toll-like receptors (TLRs) or
cytokines receptors such as tumor necrosis factor receptor 1
(TNFR1) and interleukin-1 receptor (IL-1R). Activation of these
pathways results in the induction of inflammatory genes that are
mediators or effectors of the PC stimulus. In addition to confer-
ring cytoprotection directly, the acquired IT protects the brain
by suppressing post-ischemic proinflammatory gene expression,
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Table 1 | List of preconditioning stimuli inducing ischemic tolerance.
Abbreviation Preconditioning stimulus Achieved by
IPC Ischemic preconditioning Transient focal and global cerebral
ischemia
RIPC Remote ischemic preconditioning Transient occlusion of femoral arteries,
mesenteric artery or renal artery
HPC Hypoxic preconditioning Exposure to a hypoxic gas mixture
HBO-PC Hyperoxia or hyperbaric oxygen preconditioning Exposure to hyperoxia (high oxygen
tension) or hyperbaricity (high atmospheric
pressure)
Hypo- or hyper-thermic PC Hypothermic or hyperthermic preconditioning Decrease or increase of body
temperature, respectively
Anesthetic PC Anesthetic preconditioning Inhalation of low dose isoflurane or
halothane
CSD-PC Cortical spreading depression preconditioning Propagation of depolarization wave across
the cortical surface
Seizure PC Seizure preconditioning Kainic acid injections that induce mild
epileptic activity
Exercise PC Exercise preconditioning Motor training (treadmill)
TLR-PC Toll-like receptor preconditioning Administration of low dose of TLR ligands
LPS-PC Lipopolysaccharide preconditioning Administration of low dose of bacterial
lipopolysaccharide endotoxin
microglial and endothelial activation and leukocyte infiltration
(Huang et al., 2006; Iadecola and Anrather, 2011b).
In this review we will focus on inflammatory pathways leading
to cerebral IT. We will review the signaling cascades involved in
immune activation in different PC modalities and highlight the
molecular components involved. Lastly, this review will highlight
the importance of epigenetic modifications and microRNAs in
PC-induced reprogramming of the immune system.
EVIDENCE FOR A ROLE OF INFLAMMATORY PATHWAYS IN
DIFFERENT PC PARADIGMS
A wide variety of preconditioning stimuli trigger the activation
of inflammatory pathways that lead to brain IT (Table 2). The
receptors, transducers and effector elements of these pathways are
shared among different preconditioning paradigms. For exam-
ple, TLRs are potent mediators of both ischemic (Pradillo et al.,
2009; Wang et al., 2010) and endotoxic PC (acquired by systemic
administration of LPS) (Tasaki et al., 1997; Ahmed et al., 2000;
Vartanian et al., 2011). Likewise, the TNF pathway is involved
in ischemic, hypoxic, hyperthermic and exercise-induced PC.
Although inflammatory pathways are not independently suffi-
cient for the induction of IT, there is evidence that several PC
modalities are dependent upon the induction of such pathways.
ISCHEMIC, HYPOXIC, AND HYPEROXIC PC
Short non-damaging episodes of ischemia prior to a lethal
ischemic episode leads to IT (Kirino, 2002). Cerebral IT can
be acquired by local PC, mediated either by global (Kitagawa
et al., 1990) or focal cerebral ischemia (Barone et al., 1998),
or by remote ischemic PC (RIPC), typically achieved by limb
ischemia (Tapuria et al., 2008). Although both TLR2 and
TLR4 have been implicated in the post-ischemic inflamma-
tory response (Cao et al., 2007; Abe et al., 2010; Brea et al.,
2011; Shichita et al., 2012), only TLR4 has been shown to
participate in ischemic preconditioning (IPC) (Konstantinov
et al., 2004; Pradillo et al., 2009). TLR4 signaling activates tran-
scription nuclear factor-κB (NF-κB) leading to the expression
of TNF, inducible nitric oxide (iNOS) and cyclooxygenase-2
(COX-2), which are required to evoke a PC effect (see Table 2).
Similarly, TNFR1, another central receptor of the innate immune
system and activator of NF-κB, is essential for the induc-
tion of IPC (Konstantinov et al., 2004; Pradillo et al., 2005;
Figure 1).
IT is not limited to the organ to which a stressor is applied.
A PC stimulus applied to one organ also leads to IT in other
organs, referred to remote PC (for reviews see Tapuria et al.,
2008; Anrather and Hallenbeck, 2013; Hess et al., 2013). Remote
ischemia can be achieved in rodents by transient occlusion of
one or both femoral arteries, the mesenteric artery or the renal
artery prior to cerebral ischemia. RIPC results in a decrease of the
infarct volume following cerebral ischemia [for a comprehensive
list in animal model see (Hess et al., 2013) and (Anrather and
Hallenbeck, 2013)]. The effect of RIPC on circulating immune
cells has been investigated in humans following forearm transient
ischemia (Table 2). These studies showed that the expression of
pro-inflammatory genes is down-regulated in circulating leuko-
cytes (Konstantinov et al., 2004) and neutrophil function is
altered (Shimizu et al., 2010).
Hypoxic-ischemic brain damage is mediated by TLRs (Stridh
et al., 2011). Therefore, TLRs might also trigger inflammatory
signaling in hypoxic PC (HPC), although no report to date has
confirmed their involvement. To induce HPC in rodents, animals
are placed in chambers and exposed to a hypoxic gas mixture,
usually 8% oxygen and 92% nitrogen, for 3–4 h (Yin et al., 2007;
Wacker et al., 2012). Hypoxia-inducible factor 1 (HIF-1) and
NF-κB are activated in the brain after HPC (Yin et al., 2007;
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Table 2 | Molecular inflammatory mechanisms of brain preconditioning.
PC stimulus PC type Receptors Transducers and effectors induced by PC References
Ischemia BCCAo TLR4 NF-κB, TNF-α, iNOS, COX-2 (48 h) Pradillo et al., 2009
MCAo TNFR1 TACE/TNF-α, NF-κB (48 h) Pradillo et al., 2005
TNF-α/TACE (48 h) Cárdenas et al., 2002
HO-1, COX-2/PGE2/
PI3K/Akt (24 h)
Park et al., 2008
IL-1β gene (6 h), IL-1ra (6 and 24 h) Shin et al., 2009
IL-1β (6 h) Wang et al., 2000
Remote forearm ischemia TLR4, TNFR6 HSP70, Calpastatin, TIMP1, ↓caspase-8;
PI3KCA, SNAP-23 (24 h)
Konstantinov et al., 2004
↓neutrophil adhesion and phagocytosis, IL–1β,
IL-10 (24 h and 10 days)
Shimizu et al., 2010
↓platelet activation (PMAs) (5 and 45min) Pedersen et al., 2011
Remote femoral artery ischemia ↑reperfusion (possible protection of
endothelium) (48 h)
Vlasov et al., 2005
Hypoxia 8% oxygen,
20min to 4 h
TNF-α, ceramide (24 h) Liu et al., 2000
SphK/S1P (2–4 h), HIF, SphK2, CCL2 (12–24 h) Wacker et al., 2012
neuronal CCL2 (12 h), endothelial CCL2 (2
days)
Stowe et al., 2012
PI3K/Akt/GSK-3β, NF-κB (1–24 h) (post-hypoxic
ischemia)
Yin et al., 2007
HBO-PC Hyperbaric COX-2 (1–3 days) (post-global ischemia) Cheng et al., 2011
HIF-1α, EPO (12 h) (post-MCAo) Peng et al., 2008
Normobaric hyperoxia TNF-α, TACE (24 h) Bigdeli and Khoshbaten,
2008
Hypothermia 33.0◦C, 4 h of reperfusion ↓PMN leucocytes, intercellular adhesion
molecule-1 mRNA (4–22 h) (post-MCAo)
Kawai et al., 2000
Hyperthermia 41.5–42◦C, 15min ↑Cortisol (possible prevention of BBB
disruption) (24 h)
Ikeda et al., 1999
38 or 40◦C, 6 h ↑HIF-1 alpha expression, HIF-1 binding activity
(astrocytes) (0 h)
Du et al., 2010
42–43◦C, 2 h ↑HSP70 (glial, endothelial cells) (24 h) Ota et al., 2000
Anesthetics Isoflurane or halothane ↑iNOS (6–24 h) Kapinya et al., 2002; Zhao
and Zuo, 2004
↑HO-1, NO and TNF-α (macrophages) (24 h) Li et al., 2009
CSD 0.5M KCl ↑ERK and COX-2 expression (0–8 h and 2–3
days)
Horiguchi et al., 2005,
2006
3M KCl NMDA receptor ↑TNF-α, IL–1β (4 h) Jander et al., 2001
Seizure Kainic acid, bicuculline
methiodide, or electrical
stimulation
Unknown Vezzani et al., 2002
(Continued)
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Table 2 | Continued
PC stimulus PC type Receptors Transducers and effectors induced by PC References
Exercise Treadmill ↑TNF-α (0 h) Ding et al., 2005
TLR ligands LPS TLR4 NF-κB suppression; IRF3, Ship1, Tollip, p105
(post-MCAo) (72 h)
Sly et al., 2004; Vartanian
et al., 2011
Genes related to TLR pathway and
cytokine–cytokine receptor interaction
pathway (3 h)
Marsh et al., 2009b;
Stevens et al., 2011
IRF3, IFNβ (3 and 24 h) Marsh et al., 2009b
↑Ceramide (6–12 and 48 h) Zimmermann et al., 2001
↑PMN infiltration (post-MCAo) (6 and 24 h) Ahmed et al., 2000
CpG ODN TLR9 IRF3, IRF7, type I IFN gene expression
(post-MCAo) (3 and 24 h); TNF-α (serum) (1 h)
Stevens et al., 2008, 2011
GDQ TLR7, IFNAR IRF7, IFNα (1–2 h) Leung et al., 2012
Poly-ICLC TLR3 ↑plasma levels of IL-1β, IL-6, IL-12, TNF-α, and
IFNγ compared to LPS-PC (3 h)
Packard et al., 2012
↑IFN-β (protein 6–8 h and mRNA 6–24h),
preservation of BBB endothelial cell
Gesuete et al., 2012
Pam3CSK4 TLR2 ↑zonula occludens-1 (ZO-1), no loss of
occludin protein inducing preservation of BBB
(6 and 24 h)
Hua et al., 2008
A PC stimulus (column 1) may be divided in several PC types (column 2) that through the stimulation of several receptors (column 3), activate different transducers
and effectors of inflammatory pathways (column 4), accounting for the protective mechanism of the brain. Time points in brackets indicate the time point of analysis
relative to the PC induction; post-MCAo indicates that the analysis was performed after induction of index ischemia.
ATA, atmosphere abolute pressure; BBB, Blood Brain Barrier; BCCAo, Bilateral Common Carotid Artery Occlusion; CCL2, chemokine (C-C motif) ligand; CCR1, 5,
Chemokine Receptor 1, 5; COX-2, Cyclooxygenase 2; CpG ODN, cytosine-guanine oligodeoxynucleotides; CSD, Cortical Spreading Depression, EPO, Erythropoietin;
GDQ, Gardiquimod; GSK-3β, Glycogen Synthase Kinase 3; HBO-PC, Hyperbaric Oxygen Preconditioning; HIF, Hypoxia-Inducible Factor; HO-1, Heme Oxygenase-
1; HSP70, Heat Shock Protein 70; IFN, Interferon; IFNAR, type I interferon receptor; IL-1β, Interleukin 1β; IL-1ra, IL-1 receptor antagonist; iNOS, Inducible Nitric
Oxidase Synthase; IPC, Ischemic Preconditioning; IRF, Interferon Regulatory Factor; KCl, Chloride potassium; LPS, lipopolysaccharide; MCAo, Middle Cerebral
Artery occlusion; MCPIP1, Monocyte Chemotactic Protein–Induced Protein 1; MyD88, Myeloid differentiation primary response 88; NF-κB, Nuclear Factor-κB;
NMDA, N-methyl-D-aspartate; NO, Nitric Oxide; ODN, oligodeoxynucleotide; Pam3CSL4, Pam3CysSerLys4; PGE2, Prostaglandin E2; PI3K, Phosphatidylinositol 3-
Kinase; PI3KCA-γ, PI3K catalytic subunit gamma isoform; PMA, platelet–monocyte aggregates; PMN, polymorphonuclear; Poly-ICLC, polyinosinic polycytidylic acid;
RANTES, Regulated on Activation, Normal T Cell Expressed and Secreted; S1P, Sphingosine-1-phosphate; Ship1, Src homology-2 domain-containing inositol 5-
phosphatase 1; SNAP-23, Synaptosome-associated protein-23; SphK2, Sphingosine Kinase 2; TACE, Tumor Necrosis factor-alpha-Converting Enzyme; TIMP1, Tissue
inhibitor of metalloproteinase 1; TLR, Toll-Like Receptor; TNFR, Tumor necrosis factor receptor; TNF-α, Tumor necrosis factor alpha; Tollip, toll interacting protein;
TRIF, TIR-domain-containing adapter-inducing interferon-β.
Wacker et al., 2012) leading to the expression of iNOS (Jung
et al., 2000), TNF-α (Liu et al., 2000) and chemokine (C-Cmotif)
ligand 2 (CCL2) (Stowe et al., 2012), which have been impli-
cated in establishing IT after HPC (see below section Molecular
Components of the Immune System Involved in PC).
The immune system is also involved in hyperoxic PC, which
can be achieved by either normobaric hyperoxia or hyperbaric
oxygen PC (HBO-PC). Delivering a gas mixture containing 90–
95% oxygen induces normobaric hyperoxia. HBO-PC consists of
the inspiration of an oxygen-containing gas mixture at higher
than one atmospheric absolute pressure (ATA), usually 2–2.5
ATA. Bigdeli et al. showed that rats subjected to 16 h of normo-
baric hyperoxia had reduced infarct volume after Middle Cerebral
Artery occlusion (MCAo) and that the TNF-α converting enzyme
(TACE)/TNF-α/NF-κB pathway is associated with the protec-
tive effect (Bigdeli and Khoshbaten, 2008). Moreover, COX-2
has also been reported to be a mediator of HBO-PC (Cheng
et al., 2011). Administration of the specific COX-2 inhibitor,
NS-398, before HBO exposure reversed the protective effect
of HBO-PC. Cheng et al. further identified COX-2-dependent
upregulation of HIF-1α as a possible down-stream mediator of
HBO-PC.
HYPOTHERMIC AND HYPERTHERMIC PC
Hypothermia induced during and/or after ischemia has a well-
established protective effect in acute ischemic stroke (Wu and
Grotta, 2013) and may be partly due the inhibition of the inflam-
matory response occurring during stroke (Ceulemans et al.,
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FIGURE 1 | Cytokine signaling pathways in brain preconditioning.
Following preconditioning (PC), the increase in tumor necrosis factor (TNF)-α,
interleukin (IL)-1β and IL-6 and chemokine (C-C motif) ligand 2 (CCL2) leads to
the activation of inflammatory cascades and induction of gene expression
such as inducible nitric oxide synthase (iNOS) and cyclooxygenase (COX)-2,
mediators of delayed PC. IL-6/IL-6R activates Janus kinase (JAK)-signal
transducer and activator of transcription (STAT) pathway. Phosphorylation and
nuclear translocation of STAT induces iNOS and COX-2 up-regulation (Dawn
et al., 2004). TNF-α activates TNF receptor 1(TNFR1)/Tumor necrosis factor
receptor type 1-associated DEATH domain protein (TRADD)/TNF-α
receptor–associated factor 2 (TRAF2) pathway (Hallenbeck, 2002; Pradillo
et al., 2005). Furthermore, TNF-α activation promotes ceramide synthesis that
also mediates TNFα-preconditioning (Liu et al., 2000; Ginis et al., 2002). The
neutral sphingomyelinase domain (NSD) of TNFR1 recruits factor associated
with neutral sphingomyelinase activation (FAN). FAN activates neutral
sphingomyelinase (nSMase) in the outer leaflet of the plasma membrane to
produce ceramide (Hallenbeck, 2002). IL-1R activates toll interacting protein
(tollip)/myeloid differentiation primary response 88 (MyD88)-IL-1R-associated
kinase (IRAK)/TRAF6 signaling. TRAF mediates the activation of inhibitor of
κB kinase (IKK), which triggers the phosphorylation-induced proteasomal
degradation of the IκB, NF-κB activation and subsequent iNOS and COX-2
expression. CCL2/CCR2 activation promotes phospholipase-C (PLC)-
diacylglycerol (DAG)-protein kinase C (PKC) pathway that leads to extracellular
signal-regulated kinases (ERK1/2) activation and ultimately causes NF-κB
activation (Rehni and Singh, 2012). In addition, HIF-1-induced expression of
CCL-2 confers cerebral ischemic tolerance (Stowe et al., 2012). COX-2-derived
prostaglandin E2 (PGE2) (Horiguchi et al., 2006) and iNOS-derived nitric oxide
(NO) (Cho et al., 2005) are molecular mediators of PC.
2010). Brief exposure to hyperthermia represents an additional
method of PC (Table 2). In animal model of stroke, transient
hypothermia prior an ischemic insult (Nishio et al., 2000; Yunoki
et al., 2003) or during reperfusion (Kawai et al., 2000) reduces
infarct volume. The latter study has reported a decrease number
of polymorphonuclear leucocytes during reperfusion—shown by
a reduced myeloperoxidase activity in rats subjected to hypother-
mia (Kawai et al., 2000). Hyperthermic PC reduces brain damage
in newborn rats as well (Ota et al., 2000). The protective mech-
anism of hyperthermic PC has been linked to the induction of
the heat shock protein 70 (HSP70) within glial and endothelial
cells (Ota et al., 2000). In addition to its role as an intracel-
lular chaperon, HSP70 acts as an endogenous ligand of TLR4.
Extracellular HSP70 is released from damaged cells and serves
as a damage-associated molecular pattern (DAMPs) molecule
(Bianchi, 2007). It has been shown that HSP70 mediates endo-
toxin tolerance by signaling through the TLR4/CD14 pathway
(Vabulas et al., 2002; Aneja et al., 2006), similar to the canonical
TLR4 ligand LPS. Thus, induction of HSP70 following hyperther-
mia could be a factor in the establishment of IT.
ANESTHETIC PC
Inhalation anesthetics are strong inducers of IT and can directly
modulate immune functions in neutrophils, monocytes and lym-
phocytes (Clarkson, 2007; Wang et al., 2008). Rats pretreated
with low dose isoflurane or halothane were protected after per-
manent MCAo (Kapinya et al., 2002). The protective effect was
attributed to increased iNOS expression after anesthetic PC, and
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was reversed by treating the animals with the iNOS inhibitor
aminoguanidine. Volatile anesthetics might directly alter the
response of immune cells to inflammatory stimuli. Isoflurane
PC of mouse macrophages induced the expression of heme
oxygenase-1 (HO-1) and decreased NO and TNF-α release after
subsequent LPS exposure (Li et al., 2009).
CORTICAL SPREADING DEPRESSION, BRAIN STIMULATION, AND
SEIZURES
CSD is an electrophysiological phenomenon characterized by a
slowly propagating depolarization wave across the cortical sur-
face that confers delayed IT (Yanamoto et al., 1998; Horiguchi
et al., 2006; Shpargel et al., 2008). In animal models, CSD
PC is elicited by either topical application or superfusion of
the cortical surface with a 0.5–5M KCl solution that induces
IT lasting 1–15 days (Kawahara et al., 1995; Yanamoto et al.,
1998; Horiguchi et al., 2006). The delayed tolerance induced
by CSD is protein synthesis dependent and has been linked
to the up-regulation of trophic factors and glial cell activa-
tion (Kawahara et al., 1999). On the other hand, spreading
depression in organotypic hippocampal slice cultures increases
the expression of several pro-inflammatory cytokines including
TNF-α, IL-1β, IL-1α, and IL-6 (Kunkler et al., 2004). Indeed,
in vivo experiments found an early induction of both TNF-α
and IL-1β after CSD (Jander et al., 2001). Pre-treatment with the
non-competitive N-methyl-D-aspartate (NMDA) receptor antag-
onist MK-801 completely abolished the upregulation of these
cytokines, implicating NMDA receptors as a critical element driv-
ing their production. Additionally, Horiguchi et al. reported that
CSD-induced neuroprotection against ischemic injury resulting
from MCAo is dependent upon increased COX-2 expression
(Horiguchi et al., 2005, 2006), supporting the involvement of the
inflammatory response in CSD PC.
Electrical stimulation of the cerebellar fastigial nucleus, but
not other cerebellar nuclei, can induce potent and long-lasting
protection from focal or global cerebral ischemic injury (Reis
et al., 1991, 1998; Golanov et al., 1998). At the same time, fastigial
nucleus stimulation evokes a strong anti-inflammatory response
and suppresses post-ischemic iNOS expression and brain inflam-
mation after cortical IL-1β injection (Galea et al., 1998a,b). The
effect is mediated, at least in part, by increasing the tolerance of
mitochondria to calcium overload, and suppressing the release
of mitochondrial pro-apoptototic factors induced by cerebral
ischemia (Zhou et al., 2005). The molecular mechanisms of the
protective effects on mitochondria involve upregulation of pro-
hibitin, an integral protein of the innermitochondrial membrane,
which protects mitochondrial structure and function during cell
stress (Zhou et al., 2012). Consistent with its role in PC, overex-
pression of prohibitin renders neurons more resistant to injury in
a wide variety of models (Zhou et al., 2012).
Neuroprotection against cerebral damage induced by lethal
ischemic/hypoxia or global ischemia can also be acquired through
induction of mild epileptic activity elicited by kainic acid injec-
tions (Plamondon et al., 1999; Towfighi et al., 1999). Although
the mechanisms are unknown, synthesis and release of TNF-α,
IL-1β, IL-1α, and IL-6 by glia might contribute to this tolerance
modality (Vezzani et al., 2002).
EXERCISE PC
Physical exercise prevents stroke and forced exercise training
affords neuroprotection against ischemic injury (Endres et al.,
2003). Experimentally, exercise PC can be achieved by train-
ing rodents on a motor driven treadmill for 1–3 weeks (Wang
et al., 2001; Ding et al., 2005; Curry et al., 2010). Among other
mechanisms, such as protection against the blood-brain barrier
(BBB) disruption, promotion of angiogenesis and inhibition of
apoptosis, exercise PC involves activation of the immune system
(Zhang et al., 2011). The skeletal muscle is an important source
of several cytokines, often referred to as myokines, including IL-6,
IL-8, IL-15, BDNF, LIF, and FGF21 (Pedersen, 2011). The release
of these myokines into circulation might be responsible for the
systemic effects of exercise, including its neuroprotective poten-
tial (Iadecola and Anrather, 2011b). Downstream mediators of
exercise PC may include TNF-α (Ding et al., 2005) and extra-
cellular signal-regulated kinases 1 and 2 (ERK1/2) (Guo et al.,
2008; Curry et al., 2010). In one study, exercised rats submitted to
MCAo showed reduced infarct volume when compared to non-
exercised rats and this protection was associated with a gradual
increase in the level of TNF-α in the brain over the 3 week course
of treadmill exercise (Ding et al., 2005). Pre-ischemic blockage
of TNF-α signaling with an anti-TNF-α antibody or inhibition
of ERK1/2 activation abolished the protective effect (Guo et al.,
2008). Exercise PC can also change the expression of innate
immunity receptors. Treadmill exercise decreased cerebral TLR4
receptor expression in rats, although the importance of this find-
ing as a mechanism for cerebral IT has not been investigated to
date (Zwagerman et al., 2010).
MOLECULAR COMPONENTS OF THE IMMUNE SYSTEM
INVOLVED IN PC
Inflammatory signaling is governed by a complex array of
molecules that not only modulate the response of the target
cell, but also change the local microenvironment and cellular
tissue composition by recruiting cell types that are not nor-
mally present in that tissue. This inflammatory cascade is driven
by cytokines, chemokines and their receptors and is regulated
by immunomodulatory molecules. Several of these components
have been implicated in PC. Evidence for direct involvement of
some of these immune factors in cerebral IT is summarized in
Table 3.
TLRs
The Toll receptor was first described in the context of Drosophila
embryogenesis (Anderson et al., 1985). Subsequently, it was dis-
covered that the Toll pathway is activated upon Drosophila fungal
infection revealing a role of Toll receptors in the immune response
(Lemaitre et al., 1996). Exposure of immune cells to certain
pathogens activates these receptors resulting, in the activation
of intracellular signaling pathways that lead to the expression
of genes involved in the inflammatory response. In vertebrates,
TLRs, named for their homology to the toll gene in Drosophila,
are transmembrane proteins containing domains that are able
to recognize viral or microbial components known as pathogen-
associated molecular patterns (PAMPs) (Wang et al., 2011).
Peptidoglycans (PGN), lipoproteins, lipoteichoic acids (LTA),
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Table 3 | Evidence for the involvement of inflammatory mediators in PC.
Inflammatory Deletion/ PC type (dose)/time of Index Species Outcome References
mediators Inhibitor application prior to ischemia
brain ischemia
Chemokine receptors CCL2 KO HPC 2 days prior tMCAo Mouse Reversed Stowe et al., 2012
CCL2 antibody HPC 2 days prior tMCAo Mouse Reversed Stowe et al., 2012
Cytokines recpetors TNF-α KO LPS (0.2mg/Kg) 3 days prior tMCAo Mouse Reversed Rosenzweig et al., 2007
TNF-α KO CpG ODN (1.6mg/Kg) 3 days prior tMCAo Mouse Reversed Stevens et al., 2008
TNFbp LPS (0.2mg/Kg) 2–4 days prior pMCAo SHR Reversed Tasaki et al., 1997
IL-1ra BCCo 3 days prior BCCAo Gerbil Reversed Ohtsuki et al., 1996
TLR receptors TLR2 KO Pam3CSK4 1h prior tMCAo Mouse Reversed Lu et al., 2011
TLR4 KO BCCAo 2 days prior pMCAo Mouse Partially reversed Pradillo et al., 2009
TLR7 KO GDQ (40μg/mouse) 3 days prior tMCAo Mouse Reversed Leung et al., 2009
TLRs adaptors TRIF KO LPS (0.4mg/Kg) 3 days prior tMCAo Mouse Reversed Vartanian et al., 2011
IRF3 KO LPS (0.5mg/Kg) 3 days prior tMCAo Mouse Reversed Marsh et al., 2009b
IRF3 KO CpG ODN (1.6mg/Kg) 3 days prior tMCAo Mouse Reversed Stevens et al., 2011
IRF3 KO tMCAo 3 days prior tMCAo Mouse Partially reversed Stevens et al., 2011
IRF7 KO LPS (1mg/Kg) 3 days prior tMCAo Mouse Reversed Stevens et al., 2011
IRF7 KO CpG ODN (1.6mg/Kg) 3 days prior tMCAo Mouse Reversed Stevens et al., 2011
IRF7 KO tMCAo 3 days prior tMCAo Mouse Partially reversed Stevens et al., 2011
iNOS iNOS KO tMCAo 1 day prior tMCAo Mouse Reversed Cho et al., 2005
Amino- guanidine (iNOS) tMCAO 1 day prior tMCAo Mouse Reversed Cho et al., 2005
Amino- guanidine (iNOS) LPS (0.5mg/Kg) 1 day prior tMCAo Mouse Reversed Cho et al., 2005
Amino- guanidine (iNOS) Isoflurane 1 day prior pMCAo Rat Reversed Kapinya et al., 2002
COX-2 NS-398 (COX-2) HBO 5 days prior 4VO Rat Reversed Cheng et al., 2011
Rofecoxib (COX-2) tMCAO 8h prior pMCAo Rat Reversed Park et al., 2008
NF-κB pathway DTTC (NF-κB) 4VO 3 days prior 4VO Rat Reversed Blondeau et al., 2001
κB decoy DNA (NF-κB) 4VO 3 days prior 4VO Rat Reversed Blondeau et al., 2001
DTTC (NF-κB) linolenic acid (500 nmol/Kg) 3 days prior 4VO Rat Reversed Blondeau et al., 2001
κB decoy DNA (NF-κB) linolenic acid (500 nmol/Kg) 3 days prior 4VO Rat Reversed Blondeau et al., 2001
The deletion or inhibition of chemokines, cytokines, or TLR receptors, iNOS and COX-2 molecules and TLR or NF-κB signaling components described in the table,
are able to abolish the preconditioning effect, unveiling the role of inflammatory pathways involved in IT.
4VO, 4 Vessel Occlusion; BCCAo, Bilateral Common Carotid Artery occlusion; COX-2, cyclooxygenase-2; CpG ODN, cytosine-guanine oligodeoxynucleotides; DTTC,
diethyldithiocarbamate; GDQ, Gardiquimod; HBO-PC, Hyperbaric Oxygen Preconditioning; HPC, hypoxic preconditioning; IL-1ra, Interleukin 1 Receptor Antagonist;
iNOS, inducible Nitric Oxide Synthase; IRF, Interferon (IFN)-regulatory factor; LPS, Lipopolysaccharide; pMCAo, permanent Middle Cerebral Artery occlusion; TLR,
Toll-Like Receptor; SHR, Spontaneously Hypertensive Rats; tMCAo, transient Middle Cerebral Artery occlusion; TNFbp, Tumor Necrosis Factor binding protein;
TNF-α, Tumor Necrosis Factor α; TRIF, TIR-domain-containing adapter-inducing interferon-β.
lipopolysaccharides (LPS), as well as viral and bacterial nucleic
acids, serve as PAMPs recognized by individual TLRs (Akira,
2009). To date 13 members of the TLR family have been identified
in mammals. Among the most extensively studied TLRs are TLR2
which binds to LTA component of Gram-positive bacteria and
TLR4, which recognizes LPS on the cell wall of Gram-negative
bacteria (Verstak et al., 2007). Upon ligand binding, TLRs fur-
ther signal by recruiting intracellular Toll/IL-1R (TIR)-homology
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domain containing adaptor proteins, which selectively activate
signaling cascades that lead to immune responses. Several TLR
adapter molecules that are associated with functionally differ-
ent signaling cascades, such as myeloid differentiation factor-88
(MyD88) and TIR domain containing adaptor protein inducing
interferon β (TRIF), are known to date. With the exception of
TLR3, TLRs signal through MyD88-dependent pathways, while
TLR4 can activate both MyD88-dependent and—independent
pathways (Wang et al., 2011; Mallard, 2012).
MyD88 mobilizes members of the IL-1R-associated kinase
family (IRAK) leading to nuclear translocation of the transcrip-
tion factor NF-κB. NF-κB is a major regulator of the inflam-
matory response (Li and Verma, 2002) and is responsible for
the induction of various inflammatory genes including cytokines,
chemokines, adhesion molecules, proinflammatory enzymes, and
growth factors (Pahl, 1999). NF-κB is commonly found as a het-
erodimer consisting of p50 (NFKB1) and p65 (RelA) subunits.
In resting cells, the inactive form of NF-κB is located in the
cytoplasm by association with inhibitor proteins, IκBα and IκBβ
(Baeuerle and Henkel, 1994). Upon stimulation, IκB proteins are
phosphorylated and proteolytically degraded, and NF-κB dimers
are able to translocate to the nucleus and bind to the promoter
region of target genes initiating their transcription (Baldwin,
1996). NF-κB is activated in many cell types including cells of the
central nervous system (Kaltschmidt et al., 1994). In the rodent
brain, NF-κB can be activated by numerous factors known to be
induced after ischemia-reperfusion, such as glutamate, increased
intracellular Ca2+, reactive oxygen species (ROS) and inflam-
matory cytokines (Harari and Liao, 2010). Furthermore, target
genes of NF-κB have been implicated in the pathogenesis of
cerebral ischemia, such as IL-1, IL-6, TNF-α, ICAM-1, MMP9,
COX-2, and iNOS (Baeuerle and Henkel, 1994; Allan et al., 2005;
Kaltschmidt et al., 2005; Harari and Liao, 2010). Thus, it has
been postulated that stimulation of signaling pathways that lead
to NF-κB activation are associated with detrimental outcome
in cerebral ischemia (Stephenson et al., 2000). Supporting this
notion, inhibition of NF-κB using pharmacologic agents results in
reduced infarct size after stroke in rodents (Clemens et al., 1998;
Nurmi et al., 2004). It has also been shown that mice lacking the
p50 NF-κB subunit have reduced ischemic damage (Schwaninger
et al., 1999; Nurmi, 2004). However, subsequent studies have
also revealed a deleterious effect of NF-κB inhibition in neona-
tal hypoxia (Nijboer et al., 2008) and an increase of neuronal
death after transient ischemia in p50 deficient mice (Duckworth
et al., 2006) raising the possibility for a dual role of NF-κB in
stroke.
TLR4 stimulation also leads to the activation of MyD88-
independent pathways. In this case, binding of the adaptor
molecule TRIF activates the transcription factors interferon reg-
ulatory factor 3 (IRF3) and 7 (IRF7), resulting in expression of
IFNα and IFNβ type I IFN genes (Marsh et al., 2009a; Wang
et al., 2011; Mallard, 2012) (Figure 2). Type I IFNs are released
in the extracellular space and signal in an auto- or paracrine
manner through a single heterodimeric receptor, IFNAR, to acti-
vate the JAK/STAT pathway, leading to the expression of several
chemokines such as CCL2, CCL7, and CXCL10, while inhibiting
CXCL1 and CXCL2 expression. Depending on the concentration
of IFN and type of target cell, the resulting immune response can
be pro- or anti-inflammatory (Trinchieri, 2010).
Aside from binding to PAMPs, TLRs also recognize endoge-
nous molecules known as DAMPs, which are released during
ischemic cellular injury (Chen and Nuñez, 2010). Prototypical
DAMPs released from injured cells include high-mobility group
box 1 (HMGb1) protein that activates TLR2, 4, and 9; heat
shock proteins (HSPs; TLR2, 4); RNA (TLR3); mitochondrial
DNA (TLR9); hyaluronic acid (TLR2, TLR4) and peroxiredox-
ins (TLR2, TLR4) (Chen and Nuñez, 2010; Patel et al., 2012;
Shichita et al., 2012). HMGb1 and peroxiredoxins have been
reported to increase cerebral ischemic injury by augmenting the
post-ischemic inflammatory response (Kim, 2006; Yang et al.,
2011; Shichita et al., 2012). While the role of DAMPs in cere-
bral IT has not been addressed, it has been shown that systemic
administration of HMGb1 protects against myocardial ischemia–
reperfusion injury and liver ischemia-reperfusion injury, a pro-
cess that involves TLR4 (Izuishi et al., 2006; Hu et al., 2010).
Additionally, HSP70 mediates endotoxin tolerance by signaling
through TLR4 receptors (Aneja et al., 2006). Therefore, these
findings support DAMPs to participate in the PC effect through
TLRs activation. In contrast to the detrimental effect of TLR acti-
vation in response to ischemia (Wang et al., 2011), stimulation
of some TLRs prior to ischemia provides robust neuroprotection
(Marsh et al., 2009a; Wang et al., 2011). The ability of TLR lig-
ands to induce cerebral IT was first demonstrated after systemic
administration of low-dose LPS, the major TLR4 ligand, causing
spontaneously hypertensive rats to become tolerant to subsequent
ischemic brain damage induced by MCAo (Tasaki et al., 1997).
Subsequently, LPS-induced tolerance to brain ischemia has been
demonstrated in several experimental stroke models in mice, ger-
bils and pigs (Rosenzweig et al., 2004; Hickey et al., 2007; Yu
et al., 2010). A dose below 1 mg/Kg of LPS administered 1–3
days prior to cerebral ischemia is generally used in rodents to
induce IT. Furthermore, TLR4-mutant mice were refractory to
IPC, indicating that TLR4 plays an universal role in establish-
ing IT (Pradillo et al., 2009). Comparable to TLR4, pre-treatment
with the TLR2 lipopetide ligand Pam3CysSerLys4 (Pam3CSK4)
resulted in significantly decreased cerebral infarct volume after
focal cerebral ischemia/reperfusion in mice (Hua et al., 2008).
Preservation of the BBB has been suggested to play a role in this
PC mechanism. Similarly, stimulation of TLR7 by administration
of its agonist gardiquimod, an imidazoquinoline compound, pro-
vides neuroprotection against ischemic injury and was associated
with the up-regulation of the IFN pathway and IFNα production
(Leung et al., 2012). Interestingly and in contrast to TLR4 and
TLR9 induced PC, TLR7-mediated PC was abolished in IFNAR
mutant mice. Finally, activation of TLR9 by unmethylated CpG
oligodeoxynucleotides induced IT after transient MCAo in mice
(Stevens et al., 2008). Similar to LPS-PC, the protective effect
after TLR9 stimulation lasted for up to a week and was depen-
dent on the expression of TNF-α (Figure 2A) (Stevens et al., 2008;
Marsh et al., 2009a). Accordingly, CpG oligodeoxynucleotides
administration to TNF-α null mice failed to induce IT.
IT induced by TLR activation involves the reprogramming of
inflammatory pathways. This is achieved by at least two different
mechanisms. Concomitantly with induction of pro-inflammatory
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FIGURE 2 | TLR signaling pathways in cerebral IT. (A) Preconditioning
through TLRs may be afford by exposure with low dose of
pathogen-associated molecular pattern (PAMPs) molecules (Mallard, 2012).
TLRs are localized either at the outer cell surface (TLR1, TLR2, TLR4,
and TLR6) or within endosomes (TLR7 and TLR9) (Marsh et al., 2009a).
TLR2 dimerizes with TLR1 or TLR6 and is activated upon binding of
PAMPs such as the synthetic lipopeptide Pam3CysSerLys4 (Pam3CSK4),
the non-peptide ligand lipoteichoic acid (LTA) or peptidoglycans (PGN).
TLR4 predominantly recognizes lipopolysaccharides (LPS) from
Gram-negative bacteria. TLR7 and TRL9 can be activated by the synthetic
imidazoquinoline Gardiquimod (GDQ) or small DNA such as
non-methylated cytosine-guanosine (CpG), respectively (Wang et al.,
2011). Preconditioning of TLRs will favor the activation of the myeloid
differentiation factor-88 (MyD88)-dependent pathway. Upon binding of
ligands, MyD88 is activated either directly (TLR7/9) or via the
toll-interleukin 1 receptor (TIR) domain containing adaptor protein TIRAP
(TLR2/4). The latter further mobilizes members of the IL-1R-associated
kinase family (IRAK) leading to the subsequent binding/activation of TNF
receptor associated factor-6 (TRAF6), the inhibitor of κB kinase (IKK)
complex (composed of IKKα and IKKβ) and IκB. Once IκB is
phosphorylated and degraded by the proteasome, nuclear factor-κB
(NF-κB) translocates to the nucleus leading to low level of
pro-inflammatory cytokine synthesis, such as TNF-α. TLR PC also induces
the production of several negative inhibitors of TLR signaling, targeting
mainly MyD88 and NF-κB pathways. Induction of proinflammatory
cytokines and activation of such inhibitors are required to induce a state
of ischemic tolerance (Marsh et al., 2009a; Vartanian and Stenzel-Poore,
2010; Wang et al., 2011). In addition to activating the MyD88-dependent
pathway, TLR4 signals through the MyD88-independent pathway to
activate IRF3 by sequential recruiting of the adaptor molecule TIR
inducing interferon β (TRIF) and IKKε resulting in expression of
anti-inflammatory type I interferon (IFN) genes, including IFNβ (Marsh
et al., 2009b). Type I IFNγ genes are also induced by TLR7/9 activation
through the TRAF6/IKKα pathway (Hoshino et al., 2006). (B)
Damage-associated molecular pattern (DAMPs) molecules are endogenous
ligands of TLRs produced in response to ischemic injury (Vabulas et al.,
2002). Following preconditioning, activation of TLR4/7/9 by DAMPs will fail
to activate MyD88 and the subsequent signaling molecules, such as IRAK
and NF-κB. Indeed, several inhibitors produced during the first exposition
of TLRs to exogenous stimuli will block the signaling of TLRs to NF-κB.
Whether pro-inflammatory cytokines are suppressed or up-regulated is
controversial and might be model specific (Marsh et al., 2009a; Vartanian
and Stenzel-Poore, 2010). On one hand, TLR preconditioning induces a
down-regulation of NF-κB. On the other hand, it has been shown that
neuroprotection following cerebral ischemia is achieved by an
up-regulation of the TLR-IRF axis generating an increase of TGF-β, IL-10,
IFNα, and IFNβ anti-inflammatory cytokines (Stevens et al., 2011; Leung
et al., 2012). Thus, TLR preconditioning induces a reorganization of the
TLR signaling pathways after cerebral ischemia toward TRIF/IRF signaling
that may confer protection of the brain against ischemic damage.
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mediators, activation of the MyD88-dependent pathway will
result in the upregulation of negative regulators, which pre-
vent the interaction of several adaptors along the TLR4-MyD88
pathway (Figure 2A) (Sly et al., 2004). At the same time, acti-
vating the MyD88-independent pathway evokes a type I IFN
response. Indeed, recent studies have found a neuroprotective
role of the MyD88-independent pathway in TLR-induced IT after
stroke (Marsh et al., 2009a). It has been postulated that pretreat-
ment with LPS induces a switch in the transcriptional response
to subsequent TLR4 stimulation by increasing the expression
of the IRF3-induced cytokine IFNβ (Veldhuis et al., 2003)
(Figure 2B). Consistent with this hypothesis, gene expression
analysis following LPS-PC revealed upregulation of inhibitors
of the Myd88-dependent and NF-κB pathways (Vartanian et al.,
2011). Interestingly, the expression of pro-inflammatory genes
related to the NF-κB signaling pathway was similar in both
mice undergoing LPS-PC and in control mice following cere-
bral ischemia (Figure 2B). However, the study showed that
LPS-PC increased IRF3 activity following ischemia and evoked
the upregulation of anti-inflammatory genes including TGF-
β and IL-10 (Vartanian et al., 2011). The importance of the
MyD88-independent pathway in establishing IT is further sup-
ported by the fact that LPS-PC was unable to induce IT
in TRIF- but not in Myd88-deficient mice (Vartanian et al.,
2011).
CYTOKINES
Cytokines are secreted proteins with growth, differentiation,
and activation functions that shape the nature of the immune
response. Among the more than 70 candidate cytokines, TNF-α,
IL-1, IL-6, and IL-17 play major roles in initiating and amplifying
the post-ischemic inflammatory response, while IL-10 and TGF-
β are the main anti-inflammatory factors (Iadecola and Anrather,
2011a). Since immune cells, including monocytes/macrophages,
in the periphery and microglia in the brain express TLR recep-
tors (Downes and Crack, 2010), they are capable of responding
to systemic TLR agonists used as a preconditioning stimu-
lus and modify cytokine expression or secretion (Rosenzweig
et al., 2004; Ransohoff and Brown, 2012). Accordingly, several
cytokines secreted by cells of the innate immune system have
been implicated in PC. For example, TNF-α has been identi-
fied as an essential mediator of LPS-PC. It has been shown that
LPS-preconditioned TNF-α null mice were not protected from
ischemic brain injury (Rosenzweig et al., 2007). This study con-
firmed previous findings demonstrating that administration of a
specific TNF antagonist reversed the protective effect of LPS PC
in a model of permanent focal ischemia in mice (Tasaki et al.,
1997). Similarly, upregulation of IL-1α and IL-1β after bilateral
common carotid artery occlusion (BCCAo) triggered tolerance to
global ischemia (Ohtsuki et al., 1996; Shin et al., 2009). Ohtsuki
et al. also showed that systemic delivery of either IL-1α or IL-
1β was sufficient to induce IT to a subsequent episode of lethal
global ischemia and that intraperitoneal injection of recombi-
nant human IL-1 receptor antagonist prior to IPC abolished the
neuroprotective effect.
In addition to systemic administration of cytokines, neuropro-
tection has also been reported with direct delivery of cytokines to
the brain before ischemia. Previous intracerebrovascular injection
of IL-6 in rats subjected to permanent ischemia protects from
cell death (Loddick et al., 1998). Likewise, intracisternal admin-
istration of TNF-α in mice before distal MCAo is neuroprotective
(Nawashiro et al., 1997). However, in the same study, both intra-
venous and intraperitoneal routes of TNF-α administration failed
to exert neuroprotection against cerebral ischemia. While dif-
ferences in modality of administration and stroke models may
account for the observed disparities in outcome, it remains
unclear how systemic cytokines exert their effect within the brain.
TNF-α, IL-1β, and IL-6 are transported unidirectionally across
the BBB (Banks, 2005). Thus, systemic induction of cytokines
can lead to an increase of them in the brain. For instance, IL-1
expression in the brain has been documented after an increase
of circulating IL-1 induced by LPS PC (Gabellec et al., 1995).
On the other hand, inducers of PC, such as LPS and cytokines,
can act through interaction with receptors in circumventricular
organs that lack a BBB, triggering upregulation of cytokine lev-
els in the brain. Accordingly, it has been shown that perivascular
cells and neurons in the circumventricular organs produce TNF-
α in response to systemically administered LPS (Breder et al.,
1994).
CHEMOKINES
Chemokines are small molecules involved in the recruitment of
immune cells to sites of inflammation or injury (Charo and
Ransohoff, 2006). In the central nervous system, chemokines
are highly upregulated in neuropathologic conditions. Neurons,
astrocytes, microglia, endothelial cells as well as circulating leuko-
cytes are potential sources of chemokines. Several chemokines
have been linked to the pathogenesis of ischemic brain injury
(Jaerve and Müller, 2012). Upon release, they exacerbate tis-
sue injury by increasing leukocyte and monocytes/macrophages
infiltration, potentiating neuronal injury. However, chemokines
also possess neuroprotective and neurotrophic functions (Semple
et al., 2009). The prevalence of beneficial or detrimental
effects may depend on various factors, including the type of
the chemokine, its concentration, the time course of pro-
duction relative to the time of injury and the target cell
type (Semple et al., 2009). The contribution of chemokines
to PC has been investigated in several models of IT. For
instance, HPC or BCCAo prior to transient or global MCAo
resulted in reduced infarct size attributed to CCL2 (MCP-1),
a leukocyte-derived pro-inflammatory chemokine (Rehni and
Singh, 2012; Stowe et al., 2012). Following HPC, expression
of CCL2 increased in both neurons and cerebral endothelial
cells prior to the induction of the ischemic injury. Moreover,
the induction of IT was blocked by CCL2 neutralizing anti-
bodies and was not observed in CCL2-knockout mice (Stowe
et al., 2012). Although the protection conferred by HPC is asso-
ciated with the number of CCR2+ monocytes in blood and
leaving the circulation, their direct protective role in brain IT
needs to be further characterized. Rehni et al. have shown
that IT induced by BCCAo PC was lost after treatment with
a selective antagonist of CCR2 (Rehni and Singh, 2012), cor-
roborating the role of CCL2 chemokines and its receptor
in IT.
Frontiers in Neuroscience | Neuroendocrine Science March 2014 | Volume 8 | Article 44 | 10
Garcia-Bonilla et al. Immunity and brain preconditioning
CANNABINOIDS
The endocannabinoid system consists of the cannabinoid type
1 (CB1) and type 2 (CB2) receptors and their ligands (Howlett
et al., 2002). The expression of these two receptor sub-
types varies among tissues. CB1 receptors are abundant in
the CNS and are also present in several peripheral tissues,
albeit to a lesser extent (Matsuda et al., 1990; Galiègue et al.,
1995). Although also present in the brain (Gong et al., 2006),
CB2 is mostly expressed in immune cells (Galiègue et al.,
1995). Cannabinoid receptors may be activated upon bind-
ing of their endogenous ligands arachidonoyl ethanolamide
or anandamide (AEA), 2-arachidonoylglycerol (2-AG), and
2-arachidonyl glyceryl ether (noladin ether), or synthetic analogs
which are derivatives of herbal cannabinoids, such as the ter-
penoid 9-tetrahydrocannabinol (THC), the active compound
of the cannabis plant (Di Marzo et al., 1998). Both CB1
and CB2 receptors are members of the seven-transmembrane
G-protein coupled receptor superfamily. They may initiate
downstream signaling pathways that activate potassium chan-
nels, phosphatidylinositol-3-kinase and mitogen-activated pro-
tein kinases (Di Marzo et al., 1998). The CNS endocannabinoid
system has a variety of physiological roles, which are mainly
mediated by CB1 receptors. These include, but are not lim-
ited to: psychotropic effect, pain inhibition, memory function
and increased appetite (Ameri, 1999; Pacher and Haskó, 2008).
Modulation of immune responses and the release of inflamma-
tory mediators have been primarily attributed to CB2 receptors
(Pacher et al., 2006; Ullrich et al., 2007; Elliott et al., 2011).
The endocannabinoid system has been implicated in ischemic
injury (Pacher and Haskó, 2008). Several studies have shown
a neuroprotective effect of CB activation in brain ischemia
(Nagayama et al., 1999; Panikashvili et al., 2001) by decreas-
ing intracellular Ca2+ (Zhuang et al., 2005), modulating brain
temperature (Leker et al., 2003), inhibiting pro-inflammatory
signaling cascades (Panikashvili et al., 2005) and by prevent-
ing endothelial cell activation and leukocyte adhesion (Zhang
et al., 2007, 2009). There is emerging evidence that cannabinoids
also play a role in PC. Induction of IT by electroacupuncture
PC improves neuronal survival in a rat model of focal ischemia
(Wang et al., 2005, 2009; Ma et al., 2011). While early PC in
this model was dependent on the activation of CB1 receptors as
demonstrated by the reversal of the protective effect after admin-
istration of the CB1 receptor antagonist AM251 or CB1 siRNA
(Wang et al., 2009), delayed PC was dependent upon the activa-
tion of CB2 receptors (Ma et al., 2011). It was shown that IT was
partially reversed when animals were treated with the specific CB2
antagonist AM630. Inhibition of the CB1 receptor, however, did
not block the induction of delayed IT. Although the cellular com-
ponents of this response have not been investigated, the nearly
exclusively expression of CB2 receptors on immune cells makes
it possible that modulation of the immune response accounts for
the observed neuroprotection.
iNOS
Nitric oxide (NO) is produced by nitric oxidase synthase
(NOS) through oxidation of the guanidino nitrogen of L-
arginine. Endothelial (eNOS), neuronal (nNOS) and inducible
or inflammatory (iNOS) isoforms are found in the brain, and
play important roles in IT (for recent review see (Iadecola et al.,
2011). iNOS is specifically expressed under pathological con-
ditions, typically those associated with inflammation (Nathan,
1997). Data from our laboratory have shown that iNOS medi-
ates IT following either IPC or LPS-PC in a mouse model of
transient MCAo (Cho et al., 2005). PC-mediated neuroprotection
was abolished when the selective inhibitor, aminoguanidine, was
delivered prior to PC, or when iNOS null mice were used. iNOS
expression and accumulation of peroxynitrite in cerebral blood
vessels was observed 24 h after IPC (Cho et al., 2005), whereas
LPS-PC was associated with accumulation of peroxynitrite in
neurons and vessels (Kunz et al., 2007). The role of iNOS in PC
has also been reported with anesthetic preconditioning (Kapinya
et al., 2002). Prior treatment with isoflurane or halothane, which
reduces infarct volume after permanent MCAo, induced iNOS
expression in the cortex 18–24 h after PC. Analogous to the stud-
ies mentioned above, anesthetic PC was blocked when animals
were treated with the iNOS inhibitor aminoguanidine.
COX-2
Similar to iNOS, brain cycloxygenase-2 (COX-2) is markedly
upregulated during post-ischemic inflammation and its reac-
tion products contribute to the evolution of ischemic damage
(Iadecola et al., 2001). Likewise, the role of COX-2 has been
investigated in several PC paradigms. Increased brain levels of
COX-2 following PC by CSD, was associated with the develop-
ment of cerebral IT in a rat model of MCAo (Horiguchi et al.,
2006). IPC by transient MCAo induced COX-2 and HO-1 expres-
sion, and significantly reduced infarct volume after index MCAo.
Administration of the COX-2-selective inhibitor rofecoxib abol-
ished the neuroprotective effect of IPC, indicating a key role of
COX-2 in establishing IT (Park et al., 2008). More recently, the
role of COX-2 in PC induced by HBO has also been reported
(Cheng et al., 2011). COX-2 induction is associated with pro-
tection against subsequent global cerebral occlusion in rats and
IT was abolished by treatment with COX-2 selective inhibitor
NS-398. Contrary to IPC, no role of COX-2 in LPS PC was
found in a excitotoxic model of brain injury induced by NMDA
(Kawano et al., 2007).
ROS
ROS play a key role in the pathogenesis of the ischemic cascade.
ROS are mainly generated after cerebral ischemia by the injured
tissue during the acute phase (minutes-hours) and by infiltrat-
ing leukocytes during the sub-acute ischemic phase (Chan, 2001;
Kahles et al., 2007). For example, neutrophils that infiltrate the
ischemic brain produce excessive superoxide via NADPH oxi-
dase, contributing to the exacerbation of ischemic injury (Kunz
et al., 2006; Chen et al., 2009; Pun et al., 2009). In precondi-
tioning, the role of ROS via inflammatory mechanisms has also
been reported. Kunz et al. showed improvement of cerebrovascu-
lar function after transient MCAo in LPS preconditionedmice, an
effect associated with peroxynitrite formation (Kunz et al., 2007).
Interestingly, peroxynitrite was specifically formed after PC from
the reaction of iNOS-derived NO and Nox2 (NADPH oxidase)-
derived superoxide, and was not observed in iNOS or Nox2-null
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mice. Moreover, peroxynitrite was also found to be beneficial in
the tolerance induced by LPS-PC to brain injury resulting from
cortical injection with NMDA (Kawano et al., 2007).
EPIGENETIC MECHANISMS
In delayed PC, the time window during which IT is observed can
last for days or even weeks. This contrasts with the limited dura-
tion of inflammatory signaling where responses are often short
lived, and several negative feedback loops are in place to restrict
the duration of the inflammatory response. This is achieved by
the expression of a series of cellular inhibitors that are con-
comitantly produced along with pro-inflammatory molecules,
leading to a timely termination of gene expression after the stim-
ulus subsides. These inhibitors can directly target transcription
factors, as is the case with NF-κB, which is sequestered in the
cytoplasm by newly synthetized IκB proteins—or, by inactivat-
ing key proteins within the pro-inflammatory signaling cascade.
For example, A20, an ubiquitin editing enzyme that is highly
inducible by pro-inflammatory stimuli, targets several proteins in
the TNFR signaling cascades by removing K63-linked ubiquitin
chains from TRAF2, TRAF6 and NEMO. It results in suppres-
sion of NF-κB signaling, and by replacing K63- with K48-linked
ubiquitin chains in RIP1, thus targeting it for proteasomal degra-
dation (Verstrepen et al., 2010). Similarly, suppressor of cytokine
signaling (SOCS), a family of 40 related proteins, and PIAS (pro-
tein inhibitor of activated STAT) target primarily the JAK (Janus
kinase)/STAT (signal transducer and activator of transcription)
pathway, which is the main cellular transducer of cytokine signals
(Yoshimura et al., 2007). Accordingly, short-acting inflammatory
signals, as applied during PC protocols, are transient, and not
suitable to alter the cellular state for an extended period of time.
This view is supported by experimental data in ischemic and LPS
preconditioned animals, that show transient global alterations of
gene expression profiles after PC, which have largely dissipated
by the time of index ischemia (Stenzel-Poore et al., 2003; Marsh
et al., 2009b). This raises the question of how the “memory” of
the PC event is preserved if the attendant mRNA response has
already subsided. An essential feature of such a mechanism, is
its persistence beyond the initial stimulation and its decay over
time, thus, equipping the cell or organ with a relatively short lived
memory of a previous exposure to a potentially lethal stressor.
One possibility is that the protein products of the subsided tran-
scriptional activity are still present at the time of induction of
ischemia, which could steer the response from injury toward pro-
tection. Another possibility is that the transcriptional response
to PC induces longer lasting epigenetic changes that shape the
genetic response when injurious ischemia occurs. Epigenetic
mechanisms include all processes that regulate gene expression
without alteration of the underlying DNA sequence, and include,
for example, histone modifications, DNA methylation, and
non-coding RNAs.
HISTONE AND DNA MODIFICATIONS IN PRECONDITIONING OF THE
IMMUNE SYSTEM AND THE BRAIN
Histone modifications by methylation, acetylation, phosphoryla-
tion, ubiquitination, and sumoylation are key events in regulating
chromatin structure and gene expression. The mechanism by
which these modifications alter gene expression is not entirely
understood, but may involve tethering of chromatin remodeling
machinery, transcriptional repressors and activators. While acety-
lation of N-terminal histone tails are a hallmark of actively tran-
scribed genes, it is less likely that histone acetylation plays a major
role in imprinting a lasting memory from a previous exposure.
Supporting this view is the fact that histone deacetylase (HDAC)
is recruited early to the promoter of induced genes, in most
cases during the gene activation process itself, resulting in a high
turnover rate of acetylation marks in the order of minutes and
fast disposal of this modification once transcription of the partic-
ular gene subsides (Hazzalin andMahadevan, 2005). On the other
hand, DNA methylation is a very thermostable epigenetic mark
and, with the possible exception of 5-hydroxymethylcytosine,
refractory to environmental stimuli. Therefore, DNA methyla-
tion is unsuited to act as an on-off switch for epigenetic memory
(Qureshi andMehler, 2010). Histone H3 tri-methylation at lysine
4 (H3K4me3), in contrast, has been shown to mark active or
poised enhancers for an extended period of time. In a model
of Candida albicans infected macrophages, persistent H3K4me3
modifications in the enhancer regions of inflammatory genes
was associated with a more robust inflammatory response and
reduced re-infection rate upon re-exposure (Quintin et al., 2012).
Notably, the K4 trimethylation was observed for up to a week
after deposition. The importance of H3K4me3 in changing tran-
scriptional responses has been shown in LPS-preconditioned
macrophages (Foster et al., 2007). Macrophages pre-exposed to
LPS responded to a second LPS exposure with a transcrip-
tional program distinct from that of naïve macrophages exposed
to LPS. Genes could be divided into “tolerizeable” genes (T),
which were suppressed in tolerant macrophages, and “non-
tolerizeable” genes (NT), expressed at higher levels in tolerant
than non-tolerant macrophages. It was found that promoter
regions of T-class genes were refractory to histone H4 acety-
lation and H3K4 trimethylation, two modifications positively
correlated with transcriptional activity, upon the second LPS
challenge (Foster et al., 2007). Depending on the chromatin status
in the resting state, genes can be divided in primary and sec-
ondary response genes (Ramirez-Carrozzi et al., 2006). Primary
genes show a chromatin structure that is suited for immediate
transcription and their activation is independent of new protein
synthesis. Secondary genes show histone modifications charac-
teristic of inactivated genes and the removal of this block and
gene induction is protein synthesis dependent. Interestingly, this
study found that LPS-PC changed many genes from secondary
to primary response genes upon LPS re-stimulation, further
implicating that epigenetic memory has been established in this
model.
Several histone modifiers have been implicated in the PC
response of the brain, including sirtuin family HDACs (Morris
et al., 2011) and polycomb group proteins (PcG), a multimeric
protein complex that mediates gene silencing and PC (Stapels
et al., 2010). In addition to their role in neuronal physiology,
both protein families have been implicated in the regulation of
immune function (Swigut and Wysocka, 2007; Gallí et al., 2011).
Whether they also regulate the immune signaling during PC,
however, has not been directly addressed thus far.
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MICRORNAS AND LONG NON-CODING RNAS
microRNAs (miRNAs) are small non-coding RNAs (18- to
24- nucleotides) that repress translation of mRNAs. Mature miR-
NAs are excised from a precursor RNA by the activity of Dicer and
are guided to the 3′-untranslated region (3′-UTR) of mRNAs tar-
gets by the RNA-induced silencing complex (RISC). This leads
to the down-regulation of gene expression via degradation or
translational inhibition (Bartel, 2009). miRNAs have an essen-
tial quality that makes them compatible with the maintenance
of preconditioning memory, namely their stability (Rüegger and
Großhans, 2012). In addition, they are inducible by environ-
mental stimuli, and are regulated at the levels of transcription,
biogenesis, stability and decay. Supportive for a role of some
miRNAs in establishing epigenetic memory, is the fact that they
are extremely long lived, more than 12 days in the case of miR-208
in the heart (van Rooij et al., 2007). Furthermore, ablation of
many miRNAs is well tolerated in the mouse, with these mutant
animals only developing substantially altered phenotypes after
being subjected to some kind of stress. These observations sug-
gest that the persistence of inducible miRNAs due to their long
half-lives after initial stimulation, may enable the maintenance
of gene-expression programs that enhance the resistance of cells
to repeated stress-exposure. When such “memory” miRNAs are
absent (such as in animals depleted of the genes encoding the
miRNAs), aberrant phenotypes become apparent (Leung and
Sharp, 2010). The findings that miRNA can be actively secreted
and transferred from cell-to-cell via microvesicles makes it possi-
ble that miRNA can work at a distance by transferring epigenetic
signatures from a stimulus-exposed cell to a cell that has not
encountered the particular environmental stressor (Valadi et al.,
2007).
It is estimated that 500–1000 different miRNAs are expressed
in mammalian cells and several miRNAs have been implicated
in the regulation of the immune response and inflammation
(O’Connell et al., 2012). Certain miRNAs, for instance, miR-9,
-21, -146a, -147, -203, are induced in response to TLR activa-
tion, and serve as negative feedback regulators of the MyD88-
dependent TLR signaling pathway and NF-κB activity (O’Neill
et al., 2011). Conversely, miR-155 enhances the inflammatory
response by down-regulating negative regulators Src Homology-
2 domain-containing inositol-5′-phosphatase 1 (SHIP1) and
SOCS1 leading to prolonged activation of AKT and IFN signaling
pathways (O’Connell et al., 2009).
Cerebral ischemia-reperfusion injury alters the expression
of several miRNAs (Dharap et al., 2009; Wang et al., 2013).
Interestingly, IPC and HPC have been shown to rapidly alter
miRNA levels in the brain (Dharap and Vemuganti, 2010; Lee
et al., 2010; Liu et al., 2012). Although it is unknown if these
alterations directly affect immune pathways participating in PC,
the finding that expression of miRNAs involved in inflam-
matory signaling is altered by IPC in mice, is suggestive for
such a role. For example, miR-17-5p, an inhibitor of monocyte
maturation, and the TLR4-targeting miRNA let-7e were down-
regulated in the cerebral cortex of mice after IPC (Lusardi et al.,
2010). Furthermore, the peroxisome proliferator-activated recep-
tor gamma (PPARγ)-targeting miR-27b and miR-146a, which
regulates Traf6, IRAK1, and IRAK2 expression, were up-regulated
after PC by transient MCAo in rats (Dharap and Vemuganti,
2010). The same study showed down-regulation of miR-145,
which targets the essential TLR4-associated signaling molecule
MyD88-adapter-like (MAL). Tellingly, monocyte chemotactic
protein-induced protein 1 (MCPIP1), a multifunctional protein
with RNAse activity that antagonizes Dicer, and thereby inhibits
miRNA biogenesis (Suzuki et al., 2011), has been shown to
abrogate the effects of LPS-PC in a mouse model of transient
cerebral ischemia (Liang et al., 2011). Taken together, although
PC-induced regulation of immune components by miRNA has
not been conclusively shown to contribute to cerebral IT, the cor-
relative data gathered so far are supportive for a role of miRNAs
in regulation of immune pathways during PC.
Long non-coding RNAs range from 200 bp to several kb, and
are expressed in a cell type specific manner (Mercer et al., 2009).
Although most of these molecules have not been functionally
characterized, they may have diverse roles ranging from regula-
tion of chromosome inactivation to control of gene expression
(Mercer et al., 2009). Because several long non-coding RNAs
have been shown to be inducible and are involved in regulating
immune cell activity and inflammatory signaling, they consti-
tute another potential player by which epigenetic processes can
establish a cellular memory. Their role in PC has yet to be
investigated.
CONCLUSIONS
Although post-ischemic inflammation is considered a major
pathogenic factor in stroke, emerging evidence supports a
beneficial role of selected inflammatory pathways. One such
mechanism is the induction of endogenous neuroprotection
through ischemic PC (Figure 3). The evidence summarized in
this review indicates that the immune system plays a central
role in the mechanisms eliciting neuroprotective responses after
PC. While activation of IT-inducing immune pathways shows
robust neuroprotection in animal models, the clinical transla-
tion of such approaches is complicated by side effects including
systemic inflammation and immunodepression (Meisel et al.,
2005; McColl et al., 2009). The identification of specific pathways
and effector molecules involved in establishing inflammatory PC
will help to design targeted PC protocols that can be poten-
tially translated into clinical practice (Keep et al., 2010; Anrather
and Hallenbeck, 2013; Narayanan et al., 2013). Notably, immune
pathways are not only involved in PC induced by inflammatory
mediators, but have also been implicated in several PC paradigms
that are not triggered by inflammatory signals, such as ischemic
and anesthetic PC, attesting a pivotal role for the immune system
in mediating and/or establishing IT. Because of the involvement
of inflammatory pathways in a wide variety of diseases, many
of the immune components involved in PC are prime therapeu-
tic targets and subjects of extensive drug development. Several
proteins involved in PC, such as type I IFNs, are currently in clin-
ical use, and re-purposing them for stroke therapy or prevention
could provide a fast track for clinical translation. However, much
remains to be learned. For example, few studies have investigated
the role of specific immune cells in IT, an area of research that
could result in cell-specific therapies and would therefore mitigate
the likelihood of adverse effects associated with administration
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FIGURE 3 | Inflammatory components in stroke and preconditioning.
Stroke induces a major inflammatory response through toll-like receptors
(TLRs) and tumor necrosis factor receptor (TNFR) signaling, which activate
nuclear factor-κB (NF-κB) resulting in upregulation of inflammatory
molecules, such as TNF-α, interleukin (IL)-1β, CCL2, inducible nitric oxidase
synthase (iNOS) and cyclooxygenase (COX)-2, contributing to the ischemic
brain injury. In preconditioning (PC), the exposure to a wide range of
stressors activates inflammatory pathways and leads to upregulation of
inflammatory molecules similarly to those induced by stroke. After the
effects of the stressor have subsided, the inflammatory response is
resolved during the early phase of PC and gene expression returns to basal
levels. However, longer lasting epigenetic changes induced in the immune
system components by micro-RNAs (miRNAs) and histone methylation
(i.e., histone H3 trimethylation at lysine 4, H3K4me3) may reprogram
inflammatory pathways to respond differently after an episode of severe
ischemia, for instance favoring the expression of anti-inflammatory
cytokines (IL-10, tumor growth factor-(TGF)-β and interferon-(IFN)-β that
induces ischemic tolerance (IT).
of inflammatory cytokines. In addition, a better understand-
ing of the epigenetic mechanisms involved in IT could lead to
therapies that preserve PC-induced epigenetic changes, thereby
substantially extending the time frame in which IT is observed.
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